Not finding it? Sign in to also search OpenAlex live.
-
P18.02.B ANALYSIS OF TUMOR RELAPSE PROBABILITY AND OVERALL SURVIVAL PREDICTION FOLLOWING CONCOMITANT RADIOTHERAPY WITH TEMOZOLOMIDE USING FET PET IN PATIENTS WITH GLIOBLASTOMA
Isabelle Stetter, Jan‐Michael Werner, Michael Wollring, Garry S. Ceccon, Philipp Lohmann, Gabriele Stoffels, +4 more
0citations -
NIMG-42. ANALYSIS OF TUMOR RELAPSE PROBABILITY AND OVERALL SURVIVAL PREDICTION FOLLOWING TEMOZOLOMIDE CHEMORADIATION USING FET PET INCLUDING RADIOMICS IN PATIENTS WITH GLIOBLASTOMA
Isabelle Stetter, Jan‐Michael Werner, Michael Wollring, Garry S. Ceccon, Philipp Lohmann, Keith George Ciantar, +5 more
0citations -
POS1173 LONG-TERM ANALYSIS OF RELAPSE RATES IN A EUROPEAN ANCA-ASSOCIATED VASCULITIS (AAV) COHORT FOR GPA AND MPA2023 Annals of the Rheumatic Diseases conference-abstract Medicine Vasculitis and related conditions Open access
Stefan Krämer, Thomas Rauen, K. Pruin, Teresa M Anslinger, Martin Busch, Raoul Bergner, +1 more
2citations -
Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study
Julia Marie Unglaub, Richard F. Schlenk, Maher Hanoun, Hans Christian Reinhardt, Jan Moritz Middeke, Kerstin Schäfer‐Eckart, +30 more
4citations -
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, +46 more
5citations -
Sustainable return to work after depression - A comparative study among occupational physicians and affected employees2022 Frontiers in Public Health article Health Professions Workplace Health and Well-being Open access
Richard Paulinus Ersel, Roman Pauli, Petra Maria Gaum, Jessica Lang
4citations -
Long-Term Comparative Outcomes in Relapse Activity and Disability Progression Among Anti-CD20 Therapies in Relapsing Multiple Sclerosis: An Unanchored Matching-Adjusted Indirect Comparison2026 Multiple Sclerosis and Related Disorders article Medicine Multiple Sclerosis Research Studies Open access
Ralf Gold, Amir Ansaripour, Klaus Schmierer, Michael Barnett, Hans Peter Hartung, Yamout Bassem, +8 more
0citations -
Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
Inga Hund, Maria Elena Hess, Julia Stomper, Gabriele Greve, Jan Mitschke, Christoph Niemöller, +13 more
0citations -
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner Drouet, Lutz Peter Mueller, Christoph Schmid, +30 more
0citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Ruben A. Mesa, Rami S. Komrokji, Steffen Koschmieder, +10 more
8citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +11 more
1citations -
Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Julia-Annabell Georgi, Sebastian Stasik, Michael Krämer, Tobias A.W. Holderried, Jochen J. Frietsch, Stefan Klein, +18 more
0citations -
P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT
Romain Tilmont, Ibrahim Yakoub‐Agha, Diderik-Jan Eikema, Nienke Zinger, Mathias Haenel, Nicolaas PM Schaap, +18 more
1citations -
Real-Life Data of Cyclosporine (CsA) Tapering in Patients with Very/ Severe Aplastic Anemia (v/sAA) Treated with Horse Anti-Thymocyte Globulin (hATG/CsA) Suggest Higher Risk of AA Relapse at Cyclosporine Plasma Levels below 100 Nanogram per Milliliter
Jeanette Walter, Kim Kricheldorf, Yannic Schumacher, Susanne Isfort, Jörg Chromik, Beatrice Drexler, +4 more
2citations -
False‐positive test results in diagnosing allergy to glatiramer acetate: Case report and a systematic literature review2020 Immunity Inflammation and Disease article Medicine Allergic Rhinitis and Sensitization Open access
Stefani Röseler, Friederike Leufgens, Hans Friedrich Merk, Jens Malte Baron, Silke Moll‐Slodowy, Gerda Wurpts, +1 more
2citations